Andexxa (Recombinant Factor Xa) - Adnexa net alfa: Received accelerated FDA approval in (?2018)
Mechanism of Action:
Andexanet Alfa - genetically modified variant of human factor Xa (alanine substituted for serine).
Acts by binding to Factor Xa inhibitors and neutralizes their anticoagulant effect.
This is useful to reverse the anticoagulant effect caused by Apixaban (Eliquis) and Rivaroxaban (Xarelto).
This is the second antidote approved by FDA for Factor Xa inhibitors:
First one, approved in 2015, was Idarucizumab (Praxbind) - for reversal of direct thrombin inhibitor - Dabigatran etexilate (Pradaxa).
Above information was taken from this JAMA review article: JAMA 2018;320(4):399-400.
No comments:
Post a Comment